Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022519258> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2022519258 endingPage "956" @default.
- W2022519258 startingPage "950" @default.
- W2022519258 abstract "We previously reported feasibility and efficacy of a monocentric pilot study of intensive sequential chemotherapy (ISC) in poor-risk aggressive non-Hodgkin's lymphoma (NHL) in patients < 60 years. To validate these results on a large cohort of patients, we designed a new and oligocentric study. After a COP (cyclophosphamide (Cy), vincristine (Vcr), prednisone (Pred) debulking, patients received four courses of high-dose CHOP (Cy, doxorubicin (Doxo), Ver, Pred), with the addition of etoposide and cisplatin during the two last courses. G-CSF was delivered after each cycle, and peripheral blood stem cells (PBSC) were used to support the two last cycles. Total duration of chemotherapy was 13 weeks, with a planned dose-intensity (DI) of 1420 mg/m2/week and 23 mg/m2/week for Cy and Doxo, respectively. Radiotherapy (involved fields) was then delivered for patients with node size > or = 5 cm at diagnosis. Forty-two patients were enrolled in this study; 36 completed the treatment and received 75% or more of the planned DI for both Cy and Doxo. Median duration of grade 4 neutropenia was 14 days (range, 2 to 28) for the regimen as a whole, and median duration of rehospitalization for febrile neutropenia was 18 days (range, 4 to 41). Overall response rate was 83%, with 29 patients (69%) in complete response (CR). Six patients failed to respond and one died of toxicity. With a median follow-up of 22.5 months (range, 10 to 42), the 3-year event-free survival (EFS) is 55% (95% CI, 39-71), while disease-free survival (DFS) is 79% (95% CI, 63-95). Ambulatory ISC is accessible and feasible in an oligocentric study. PBSC allow repeated delivery of high-dose chemotherapy cycles, and result in encouraging CR, EFS, and DFS rates for poor-risk aggressive NHL's patients." @default.
- W2022519258 created "2016-06-24" @default.
- W2022519258 creator A5003507788 @default.
- W2022519258 creator A5021314773 @default.
- W2022519258 creator A5022075377 @default.
- W2022519258 creator A5022161221 @default.
- W2022519258 creator A5043613589 @default.
- W2022519258 creator A5044335760 @default.
- W2022519258 creator A5044899765 @default.
- W2022519258 creator A5047798037 @default.
- W2022519258 creator A5059804319 @default.
- W2022519258 creator A5067988180 @default.
- W2022519258 creator A5072045610 @default.
- W2022519258 creator A5077863801 @default.
- W2022519258 creator A5085831038 @default.
- W2022519258 date "1999-06-01" @default.
- W2022519258 modified "2023-10-15" @default.
- W2022519258 title "Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high–intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin’s lymphoma: an oligocentric report on 42 patients" @default.
- W2022519258 doi "https://doi.org/10.1038/sj.leu.2401444" @default.
- W2022519258 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10360385" @default.
- W2022519258 hasPublicationYear "1999" @default.
- W2022519258 type Work @default.
- W2022519258 sameAs 2022519258 @default.
- W2022519258 citedByCount "13" @default.
- W2022519258 crossrefType "journal-article" @default.
- W2022519258 hasAuthorship W2022519258A5003507788 @default.
- W2022519258 hasAuthorship W2022519258A5021314773 @default.
- W2022519258 hasAuthorship W2022519258A5022075377 @default.
- W2022519258 hasAuthorship W2022519258A5022161221 @default.
- W2022519258 hasAuthorship W2022519258A5043613589 @default.
- W2022519258 hasAuthorship W2022519258A5044335760 @default.
- W2022519258 hasAuthorship W2022519258A5044899765 @default.
- W2022519258 hasAuthorship W2022519258A5047798037 @default.
- W2022519258 hasAuthorship W2022519258A5059804319 @default.
- W2022519258 hasAuthorship W2022519258A5067988180 @default.
- W2022519258 hasAuthorship W2022519258A5072045610 @default.
- W2022519258 hasAuthorship W2022519258A5077863801 @default.
- W2022519258 hasAuthorship W2022519258A5085831038 @default.
- W2022519258 hasBestOaLocation W20225192581 @default.
- W2022519258 hasConcept C121608353 @default.
- W2022519258 hasConcept C126322002 @default.
- W2022519258 hasConcept C141071460 @default.
- W2022519258 hasConcept C2776694085 @default.
- W2022519258 hasConcept C2776755627 @default.
- W2022519258 hasConcept C2777063308 @default.
- W2022519258 hasConcept C2778119113 @default.
- W2022519258 hasConcept C2778476033 @default.
- W2022519258 hasConcept C2778850193 @default.
- W2022519258 hasConcept C2779338263 @default.
- W2022519258 hasConcept C2779429289 @default.
- W2022519258 hasConcept C2779725641 @default.
- W2022519258 hasConcept C2780427987 @default.
- W2022519258 hasConcept C2780653079 @default.
- W2022519258 hasConcept C2781100745 @default.
- W2022519258 hasConcept C2781214270 @default.
- W2022519258 hasConcept C2781413609 @default.
- W2022519258 hasConcept C71924100 @default.
- W2022519258 hasConcept C90924648 @default.
- W2022519258 hasConceptScore W2022519258C121608353 @default.
- W2022519258 hasConceptScore W2022519258C126322002 @default.
- W2022519258 hasConceptScore W2022519258C141071460 @default.
- W2022519258 hasConceptScore W2022519258C2776694085 @default.
- W2022519258 hasConceptScore W2022519258C2776755627 @default.
- W2022519258 hasConceptScore W2022519258C2777063308 @default.
- W2022519258 hasConceptScore W2022519258C2778119113 @default.
- W2022519258 hasConceptScore W2022519258C2778476033 @default.
- W2022519258 hasConceptScore W2022519258C2778850193 @default.
- W2022519258 hasConceptScore W2022519258C2779338263 @default.
- W2022519258 hasConceptScore W2022519258C2779429289 @default.
- W2022519258 hasConceptScore W2022519258C2779725641 @default.
- W2022519258 hasConceptScore W2022519258C2780427987 @default.
- W2022519258 hasConceptScore W2022519258C2780653079 @default.
- W2022519258 hasConceptScore W2022519258C2781100745 @default.
- W2022519258 hasConceptScore W2022519258C2781214270 @default.
- W2022519258 hasConceptScore W2022519258C2781413609 @default.
- W2022519258 hasConceptScore W2022519258C71924100 @default.
- W2022519258 hasConceptScore W2022519258C90924648 @default.
- W2022519258 hasIssue "6" @default.
- W2022519258 hasLocation W20225192581 @default.
- W2022519258 hasLocation W20225192582 @default.
- W2022519258 hasOpenAccess W2022519258 @default.
- W2022519258 hasPrimaryLocation W20225192581 @default.
- W2022519258 hasRelatedWork W2006707835 @default.
- W2022519258 hasRelatedWork W2034539865 @default.
- W2022519258 hasRelatedWork W2121694206 @default.
- W2022519258 hasRelatedWork W2135181663 @default.
- W2022519258 hasRelatedWork W2155499847 @default.
- W2022519258 hasRelatedWork W2183352065 @default.
- W2022519258 hasRelatedWork W2252336101 @default.
- W2022519258 hasRelatedWork W2411674742 @default.
- W2022519258 hasRelatedWork W2412181118 @default.
- W2022519258 hasRelatedWork W2470307162 @default.
- W2022519258 hasVolume "13" @default.
- W2022519258 isParatext "false" @default.
- W2022519258 isRetracted "false" @default.
- W2022519258 magId "2022519258" @default.
- W2022519258 workType "article" @default.